Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Cited by (1,009)

Items 101–200 of 1,009

1. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
   Erin, Nuray, Grahovac, Jelena, Brozovic, Anamaria, Efferth, Thomas · 2020 · Drug Resistance Updates
2. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
   Scharping, Nicole E., Menk, Ashley V., Whetstone, Ryan D., Zeng, Xue, Delgoffe, Greg M. · 2017 · Cancer Immunology Research
3. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
   Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K. et al. · 2020 · Nature Medicine
4. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
   Diana M. Merino, Lisa M. McShane, David A. Fabrizio, Vincent Anthony Funari, Shu‐Jen Chen, James Robert White, Paul Wenz, Jonathan F. Baden, J. Carl Barrett, Ruchi Chaudhary et al. · 2020 · Journal for ImmunoTherapy of Cancer
5. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data
   Duanchen Sun, Xiangnan Guan, Amy E. Moran, Ling‐Yun Wu, David Z. Qian, Pepper S. Schedin, Mu‐Shui Dai, Alexey Valeryevich Danilov, Joshi J. Alumkal, Andrew Adey et al. · 2021 · Nature Biotechnology
6. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
   Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández et al. · 2018 · Science Translational Medicine
7. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
   Margaret L. Axelrod, Rebecca S. Cook, Douglas Buckner Johnson, Justin Micah Balko · 2018 · Clinical Cancer Research
8. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
   Chenjing Zhu, Yuquan Wei, Xiawei Wei · 2019 · Molecular Cancer
9. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
   Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan D. Emberley, Tony Chieh‐Ting Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele M. Marguier et al. · 2017 · Journal for ImmunoTherapy of Cancer
10. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
    Suzanne George, Diana Miao, George D. Demetri, Dennis O. Adeegbe, Scott J. Rodig, Sachet Ashok Shukla, Mikel Lipschitz, Ali Amin‐Mansour, Chandrajit P. Raut, Scott L. Carter et al. · 2017 · Immunity
11. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Johnson, Douglas B., Frampton, Garrett M., Rioth, Matthew J., Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C., Fabrizio, David, Chalmers, Zachary R., Greenbowe, Joel et al. · 2016 · Cancer Immunology Research
12. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
    Martin Lauss, Marco Donia, Katja Harbst, Rikke Sick Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon‐Christersson, Therese Törngren, Anders Kvist et al. · 2017 · Nature Communications
13. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Pengfei Wang, Yang Chen, Siying Song, Tingjian Wang, Wenjun Ji, Shouwei Li, Ning Liu, Changxiang Yan · 2017 · Frontiers in Pharmacology
14. Resistance Mechanisms to Anti-PD Cancer Immunotherapy
    Vesely, Matthew D., Zhang, Tianxiang, Chen, Lieping · 2022 · Annual Review of Immunology
15. Diffuse Glioma Heterogeneity and Its Therapeutic Implications
    James Nicholson, Howard Alan Fine · 2021 · Cancer Discovery
16. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
    Masaru Katoh · 2017 · International Journal of Oncology
17. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
    Yu Kato, Kimiyo Tabata, Takayuki Kimura, Ayako Yachie‐Kinoshita, Yoichi Ozawa, Kazuhiko Yamada, Junichi Ito, Sho Tachino, Yusaku Hori, Masahiro Matsuki et al. · 2019 · PLoS ONE
18. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Tuba Nur Gide, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long · 2017 · Clinical Cancer Research
19. Cellular Plasticity in Cancer
    Salina Yuan, Robert J. Norgard, Ben Z. Stanger · 2019 · Cancer Discovery
20. Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
    Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia et al. · 2017 · Cancer Research
21. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
    Leko, Vid, Rosenberg, Steven A. · 2020 · Cancer Cell
22. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
    Brigette B.Y. Ma, Wan‐Teck Lim, Boon Cher Goh, Edwin Pun Hui, Kwok Wai Lo, Adam M. Pettinger, Nathan R. Foster, Jonathan Wesley Riess, Mark Agulnik, Alex Y. Chang et al. · 2018 · Journal of Clinical Oncology
23. Genomic correlates of response to immune checkpoint blockade
    Keenan, Tanya E., Burke, Kelly P., Van Allen, Eliezer M. · 2019 · Nature Medicine
24. Neutrophil profiling illuminates anti-tumor antigen-presenting potency
    Yingcheng Charles Wu, Jiaqiang Ma, Xupeng Yang, Nan Fang, Tiancheng Zhang, Shuyi Ji, Dongning Rao, Hua Feng, Ke Gao, Xixi Gu et al. · 2024 · Cell
25. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells
    Lawson, Keith A., Sousa, Cristovão M., Zhang, Xiaoyu, Kim, Eiru, Akthar, Rummy, Caumanns, Joseph J., Yao, Yuxi, Mikolajewicz, Nicholas, Ross, Catherine, Brown, Kevin R. et al. · 2020 · Nature
26. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
    Tran, Eric, Robbins, Paul F, Rosenberg, Steven A · 2017 · Nature Immunology
27. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
    David H. Peng, B. Leticia Rodriguez, Lixia Diao, Limo Chen, Jing Wang, Lauren A. Byers, Ying Wei, Harold A. Chapman, Mitsuo Yamauchi, Carmen Behrens et al. · 2020 · Nature Communications
28. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
    Andrews, Miles C., Duong, Connie P. M., Gopalakrishnan, Vancheswaran, Iebba, Valerio, Chen, Wei-Shen, Derosa, Lisa, Khan, Md Abdul Wadud, Cogdill, Alexandria P., White, Michael G., Wong, Matthew C. et al. · 2021 · Nature Medicine
29. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
    Qingyang Lei, Dan Wang, Kai Sun, Liping Wang, Yi Zhang · 2020 · Frontiers in Cell and Developmental Biology
30. New insights into the role of <scp>EMT</scp> in tumor immune escape
    Terry, Stéphane, Savagner, Pierre, Ortiz‐Cuaran, Sandra, Mahjoubi, Linda, Saintigny, Pierre, Thiery, Jean‐Paul, Chouaib, Salem · 2017 · Molecular Oncology
31. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors
    Ford, Kirsty, Hanley, Christopher J., Mellone, Massimiliano, Szyndralewiez, Cedric, Heitz, Freddy, Wiesel, Philippe, Wood, Oliver, Machado, Maria, Lopez, Maria-Antoinette, Ganesan, Anusha-Preethi et al. · 2020 · Cancer Research
32. Organoid Models of Tumor Immunology
    Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin Jay Kuo · 2020 · Trends in Immunology
33. New perspectives for targeting RAF kinase in human cancer
    Karoulia, Zoi, Gavathiotis, Evripidis, Poulikakos, Poulikos I. · 2017 · Nature Reviews Cancer
34. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
35. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
    Jayaprakash, Priyamvada, Ai, Midan, Liu, Arthur, Budhani, Pratha, Bartkowiak, Todd, Sheng, Jie, Ager, Casey, Nicholas, Courtney, Jaiswal, Ashvin R., Sun, Yanqiu et al. · 2018 · Journal of Clinical Investigation
36. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
    Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke · 2018 · Cancer Immunology Research
37. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
    Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu, Chengzeng Wang · 2023 · Molecular Cancer
38. Androgen receptor activity in T cells limits checkpoint blockade efficacy
    Xiangnan Guan, Fanny Polesso, Chaojie Wang, Archana Sehrawat, Reed M. Hawkins, Susan Murray, GEORGE V. THOMAS, Breanna Caruso, Reid F. Thompson, Mary Ann Wood et al. · 2022 · Nature
39. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
    Grasso, Catherine S., Tsoi, Jennifer, Onyshchenko, Mykola, Abril-Rodriguez, Gabriel, Ross-Macdonald, Petra, Wind-Rotolo, Megan, Champhekar, Ameya, Medina, Egmidio, Torrejon, Davis Y., Shin, Daniel Sanghoon et al. · 2020 · Cancer Cell
40. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
    Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han · 2018 · Journal of Hematology & Oncology
41. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
    Yochai Wolf, Osnat Bartok, Sushant Patkar, Gitit Bar Eli, Sapir Cohen, Kevin Litchfield, Ronen Levy, Alejandro Jiménez-Sánchez, Sophie Trabish, Joo Sang Lee et al. · 2019 · Cell
42. Phenotype plasticity as enabler of melanoma progression and therapy resistance
    Arozarena, Imanol, Wellbrock, Claudia · 2019 · Nature Reviews Cancer
43. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance
    Phillip M. Galbo, Xingxing Zang, Deyou Zheng · 2021 · Clinical Cancer Research
44. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
    Alba Nicolás‐Boluda, Javier Vaquero, Lene Vimeux, Thomas Guilbert, Sarah Ghamry-Barrin, Chahrazade Kantari‐Mimoun, Matteo Ponzo, Gilles Renault, Piotr Deptuła, Katarzyna Pogoda et al. · 2021 · eLife
45. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
    Nicolás A. Giraldo, Étienne Becht, Yann Alexandre Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sánchez-Salas, Alexandre Ingels, Stéphane Marie. Oudard, Audrey Moatti et al. · 2017 · Clinical Cancer Research
46. Improving radiotherapy in cancer treatment: Promises and challenges
    Helen H.W. Chen, Macus Tien Kuo · 2017 · Oncotarget
47. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
    Yi Liu, Guanghao Liang, Hongjiao Xu, Wenxin Dong, Ze Dong, Zhiwei Qiu, Zihao Zhang, Fangle Li, Yue Huang, Yilin Li et al. · 2021 · Cell Metabolism
48. Dissecting Esophageal Squamous-Cell Carcinoma Ecosystem by Single-Cell Transcriptomic Analysis
    Xiannian Zhang, Linna Peng, Yingying Luo, Shaosen Zhang, Yang Pu, Yamei Chen, Wenjia Guo, Jiacheng Yao, Mingming Shao, Wenyi Fan et al. · 2020 · Nature Communications
49. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
    Kugel, Curtis H., Douglass, Stephen M., Webster, Marie R., Kaur, Amanpreet, Liu, Qin, Yin, Xiangfan, Weiss, Sarah A., Darvishian, Farbod, Al-Rohil, Rami N., Ndoye, Abibatou et al. · 2018 · Clinical Cancer Research
50. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
51. Hyperprogressive disease: recognizing a novel pattern to improve patient management
    Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté · 2018 · Nature Reviews Clinical Oncology
52. Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
    Sadegh Saghafinia, Marco Mina, Nicolò Riggi, Douglas Hanahan, Giovanni Ciriello · 2018 · Cell Reports
53. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
    David Tamborero, Carlota Rubio-Pérez, Ferran Muiños, Radhakrishnan Sabarinathan, Josep Maria Piulats, Aura Muntasell, Rodrigo Dienstmann, Núria López-Bigas, Abel González-Pérez · 2018 · Clinical Cancer Research
54. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
    Feifei Hu, Chunjie Liu, Lanlan Liu, Qiong Zhang, An‐Yuan Guo · 2020 · Briefings in Bioinformatics
55. Exploring immunotherapy in colorectal cancer
    Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang · 2022 · Journal of Hematology &amp; Oncology
56. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ
    Chang Liu, Maria D. Chikina, Rahul Deshpande, Ashley V. Menk, Ting Wang, Tracy Tabib, Erin A. Brunazzi, Kate M. Vignali, Ming Sun, Donna Beer Stolz et al. · 2019 · Immunity
57. Implementing TMB measurement in clinical practice: considerations on assay requirements
    Reinhard Büttner, John W. Longshore, Fernando López‐Ríos, Sabine Merkelbach‐Bruse, Nicola Normanno, Étienne Rouleau, Frederique Madeleine Penault-Llorca · 2019 · ESMO Open
58. Giving AXL the axe: targeting AXL in human malignancy
    Carl Michael Gay, Kavitha Balaji, Lauren A. Byers · 2017 · British Journal of Cancer
59. High response rate to PD-1 blockade in desmoplastic melanomas
    Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee et al. · 2018 · Nature
60. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
    Elizabeth R. Plimack, Joaquim Bellmunt B, Shilpa Gupta, Raanan Berger, Laura Q.M. Chow, Jonathan Wes Juco, Jared K. Lunceford, Sanatan Saraf, Rodolfo F. Perini, Peter H. O’Donnell · 2017 · The Lancet Oncology
61. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
    Ik Sun Kim, Yang Gao, Thomas Welte, Hai Wang, Jun Liu, Mahnaz Janghorban, Kuanwei Sheng, Yichi Niu, Amit Goldstein, Na Zhao et al. · 2019 · Nature Cell Biology
62. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
    Matteo Berti, David Cortez, Massimo Lopes · 2020 · Nature Reviews Molecular Cell Biology
63. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
    Daniel Zingg, Natalia Arenas-Ramirez, Dilara Şahin, Rodney Alexander Rosalia, Ana T. Antunes, Jessica Häusel, Lukas Sommer, Onur Boyman · 2017 · Cell Reports
64. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
    Chabanon, Roman M., Muirhead, Gareth, Krastev, Dragomir B., Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu et al. · 2019 · Journal of Clinical Investigation
65. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
    Florian Rambow, Jean‐Christophe Marine, Colin R. Goding · 2019 · Genes & Development
66. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Weijie Ma, Barbara M. Gilligan, Jianda D. Yuan, Tianhong Li · 2016 · Journal of Hematology & Oncology
67. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy
    Lindeboom, Rik G. H., Vermeulen, Michiel, Lehner, Ben, Supek, Fran · 2019 · Nature Genetics
68. Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
    Michal Harel, Rona Ortenberg, Siva Karthik Varanasi, Kailash Chandra Mangalhara, Mariya Mardamshina, Ettai Markovits, Erez N. Baruch, Victoria Tripple, May Arama-Chayoth, Eyal Greenberg et al. · 2019 · Cell
69. Intron retention is a source of neoepitopes in cancer
    Alicia Smart, Claire A. Margolis, Harold Pimentel, Meng Xiao He, Diana Miao, Dennis O. Adeegbe, Tim Fugmann, Kwok‐Kin Wong, Eliezer M. Van Allen · 2018 · Nature Biotechnology
70. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
    Antoni Ribas, Donald P. Lawrence, Victoria G. Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo Salvatore Carlino, Rosalie Anne Fisher, Georgina Venetia Long, Frank Stephen Hodi, Jennifer Tsoi et al. · 2019 · Nature Medicine
71. Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
    Yao Xiao, Tian Zhang, Xianbin Ma, Qi‐Chao Yang, Leilei Yang, Shao‐Chen Yang, Mengyun Liang, Zhigang Xu, Zhi‐Jun Sun · 2021 · Advanced Science
72. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
    Chun Gwon Park, Christina Hartl, Daniela Schmid, Ellese M. Carmona, Hye‐Jung Kim, Michael S. Goldberg · 2018 · Science Translational Medicine
73. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
    William H. Tomaszewski, Luis A Sanchez-Perez, Thomas Frank Gajewski, John Howard Sampson · 2019 · Clinical Cancer Research
74. Deep learning-based prediction of the T cell receptor–antigen binding specificity
    Lu, Tianshi, Zhang, Ze, Zhu, James, Wang, Yunguan, Jiang, Peixin, Xiao, Xue, Bernatchez, Chantale, Heymach, John V., Gibbons, Don L., Wang, Jun et al. · 2021 · Nature Machine Intelligence
75. Biomarker-guided therapy for colorectal cancer: strength in complexity
    Sveen, Anita, Kopetz, Scott, Lothe, Ragnhild A. · 2020 · Nature Reviews Clinical Oncology
76. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
    Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M. Kass, Maria Jasin · 2017 · Annual Review of Cancer Biology
77. Exhaustion-associated regulatory regions in CD8 + tumor-infiltrating T cells
    Giuliana P. Mognol, Roberto Spreafico, Victor Wong, James P Scott-Browne, Susan Togher, Alexander Hoffmann, Patrick G. Hogan, Anjana Rao, Sara Trifari · 2017 · Proceedings of the National Academy of Sciences
78. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
    Wang, Li, Saci, Abdel, Szabo, Peter M., Chasalow, Scott D., Castillo-Martin, Mireia, Domingo-Domenech, Josep, Siefker-Radtke, Arlene, Sharma, Padmanee, Sfakianos, John P., Gong, Yixuan et al. · 2018 · Nature Communications
79. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
    Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Xuesong Liu · 2019 · eLife
80. Overcoming resistance to tumor-targeted and immune-targeted therapies
    Aldea, Mihaela, Andre, Fabrice, Marabelle, Aurelien, Dogan, Semih, Barlesi, Fabrice, Soria, Jean-Charles · 2021 · Cancer Discovery
81. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
82. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
    Diego Chowell, Chirag Krishna, Federica Pierini, Vladimir Makarov, Naiyer A. Rizvi, Fengshen Kuo, Luc G.T. Morris, Nadeem Riaz, Tobias L. Lenz, Timothy An-thy Chan · 2019 · Nature Medicine
83. T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
    Neubert, Natalie J., Schmittnaegel, Martina, Bordry, Natacha, Nassiri, Sina, Wald, Noémie, Martignier, Christophe, Tillé, Laure, Homicsko, Krisztian, Damsky, William, Maby-El Hajjami, Hélène et al. · 2018 · Science Translational Medicine
84. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
    Smith, Christof C., Beckermann, Kathryn E., Bortone, Dante S., De Cubas, Aguirre A., Bixby, Lisa M., Lee, Samuel J., Panda, Anshuman, Ganesan, Shridar, Bhanot, Gyan, Wallen, Eric M. et al. · 2018 · Journal of Clinical Investigation
85. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
    Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna R. Parikh, Genevieve Marie Boland · 2024 · Nature reviews. Cancer
86. Heterogeneity of the tumor immune microenvironment and its clinical relevance
    Qingzhu Jia, Aoyun Wang, Yixiao Yuan, Bo Zhu, Haixia Long · 2022 · Experimental Hematology and Oncology
87. A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
    Joseph Cursons, Fernando Souza-Fonseca-Guimarães, Momeneh Foroutan, Ashley Anderson, Frédéric Hollande, Soroor Hediyeh-zadeh, Andreas Behren, Nicholas D. Huntington, Melissa J. Davis · 2019 · Cancer Immunology Research
88. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
    Joo Sang Lee, Lital N. Adler, Hiren Karathia, Narin Nard Carmel, Shiran Rabinovich, Noam Auslander, Rom Keshet, Noa Stettner, Alon Silberman, Lilach Agemy et al. · 2018 · Cell
89. Immunotherapy, Inflammation and Colorectal Cancer
    Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
90. Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization
    Fei Linda Zhao, Christine Xiao, Kathy S. Evans, Tbalamayooran Theivanthiran, Nicholas C. DeVito, Alisha Holtzhausen, Juan Liu, Xiaojing Liu, David Boczkowski, Smita K. Nair et al. · 2018 · Immunity
91. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
    Li, Xin, Xiang, Yanwei, Li, Fulun, Yin, Chengqian, Li, Bin, Ke, Xisong · 2019 · Frontiers in Immunology
92. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
    Ashton Anthony Connor, Robert Edward Denroche, Gun Ho Jang, Lee E. Timms, Sangeetha N. Kalimuthu, Iris Selander, Treasa A. McPherson, Gavin W. Wilson, Michelle Chan‐Seng‐Yue, Ivan Borozan et al. · 2016 · JAMA Oncology
93. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
94. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
    Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo Salvatore Carlino, Alexander Maxwell Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yee Hwa Yang et al. · 2020 · Nature Communications
95. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance
    Gh. Rasool Bhat, Itty Sethi, Hana Q. Sadida, Bilal Rah, Rashid Mir, Naseh A. Algehainy, Ibrahim Altedlawi Albalawi, Tariq Masoodi, Gowtham Kumar Subbaraj, Farrukh Jamal et al. · 2024 · Cancer and Metastasis Reviews
96. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
    Hongzhong Li, Yi Qun Xiao, Qin Li, Jun Yao, Xiangliang Yuan, Yuan Zhang, Xuedong Yin, Yohei Saito, Huihui Fan, Ping Li et al. · 2021 · Cancer Cell
97. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α
    Lijian Wu, Yiteng Jin, Xi Zhao, Kaiyang Tang, Yaoning Zhao, Linjie Tong, Xuerong Yu, Ke Xiong, Ce Luo, Jiajun Zhu et al. · 2023 · Cell Metabolism
98. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
99. Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
    Liam Jenkins, Ute Jungwirth, Alexandra Avgustinova, Marjan Iravani, Adam Mills, Syed Aleem Haider, James A. Harper, Clare M. Isacke · 2022 · Cancer Research
100. Immunotherapy of Melanoma: Facts and Hopes
     Sarah Ann Weiss, Jedd D. Wolchok, Mario Sznol · 2019 · Clinical Cancer Research